Status:

RECRUITING

Optimizing Recruitment to Drive Equitable Research Opportunity in Stroke Rehabilitation Trials in Canada

Lead Sponsor:

McMaster University

Conditions:

Stroke

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Stroke is a major health issue in Canada. Stroke affects over 400,000 Canadians, and this number is expected to nearly double by 2038. Research studies in stroke recovery can help us better understand...

Detailed Description

Clinical trials in stroke recovery are essential for establishing effective treatments, yet important groups, such as women and people with aphasia, have been consistently under-represented in stroke ...

Eligibility Criteria

Inclusion

  • Primary ischemic anterior circulation stroke
  • Age ≥18 years
  • ≥5 days but \<8 weeks after stroke on the date of medication (Maraviroc or placebo) start
  • Hemiparesis requiring inpatient rehabilitation
  • Assistance available for daily rehabilitation training practice and for transportation when needed
  • Adequate language skills to understand Informed Consent and retain information during daily therapies
  • At least one of the following: some shoulder abduction with gravity eliminated and visible extension in two or more digits OR visible hip flexion or extension

Exclusion

  • Pre-stroke modified Rankin score ≥2
  • Limited resources or illness that will not enable a return to living outside of a facility
  • History of dementia
  • History of hepatitis or elevated hepatic transaminases or bilirubin
  • History of renal insufficiency or creatinine clearance (eGFR) \<60mL / min / 1.73m2
  • Cancer or other chronic illness that makes 1-year survival unlikely or will detract from the ability to carry out exercise and skills practice
  • Existing pre-stroke serious disabling disease (e.g., Parkinson's disease, severe traumatic brain injury, amputation)
  • Seizure related to stroke
  • Acute or chronic epilepsy
  • Currently taking any of the following anticonvulsant medications: Carbamazepine, Phenobarbital, Phenytoin
  • Pregnant, breastfeeding, or positive test for pregnancy at baseline
  • Women of childbearing potential who are not using one highly effective form of contraception or two forms of effective contraception
  • Known HIV positivity
  • Currently taking any of the following antifungal and/or antibacterial medications: Ketoconazole, Itraconazole, Voriconazole, Rifampin, Clarithromycin, Rifabutin + Protease Inhibitor
  • Currently taking St. John's Wort

Key Trial Info

Start Date :

June 16 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

June 30 2027

Estimated Enrollment :

120 Patients enrolled

Trial Details

Trial ID

NCT06576089

Start Date

June 16 2025

End Date

June 30 2027

Last Update

September 26 2025

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

University of Calgary & Foothills Medical Centre

Calgary, Alberta, Canada, T2N 2T9

2

University of British Columbia & GF Strong Rehabilitation Centre

Vancouver, British Columbia, Canada, V5Z 2G9

3

Dalhousie University

Halifax, Nova Scotia, Canada, B3H 3J5

4

Parkwood Institute

London, Ontario, Canada, N6C 0A7